$RDY News

Reported Saturday, Dr. Reddy's Breaks Ground As First Generic Semaglutide Injection Launcher In Canada, Expanding Global GLP-1 Therapy Access

Dr. Reddy's Launches Generic Semaglutide In Canada, Expands GLP-1 Push

Dr. Reddy's Laboratories Limited (RDY) Q4 2026 Earnings Call Transcript

Dr Reddy's Laboratories Q4 EPS $0.03 Misses $0.09 Estimate, Sales $821.821M Miss $866.120M Estimate

Dr. Reddy's Laboratories (NYSE:RDY): A Peter Lynch GARP Candidate in the Pharmaceuticals Space

Dr. Reddy’s Laboratories (RDY) Announces Rollout of Injectable Semaglutide Under Brand Name Obeda®

Asian Equities Traded in the US as American Depositary Receipts Rise in Friday Trading

Asian Equities Traded in the US as American Depositary Receipts Rising in Wednesday Trading

Asian Equities Traded in US as ADRs Fall in Tuesday Trading

Asian Equities Traded in the US as American Depositary Receipts Open Week Lower in Monday Trading

Peter Lynch's GARP Strategy Identifies DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) as a Candidate

Asian Equities Traded in the US as American Depositary Receipts Little Changed in Thursday Trading

Dr. Reddy's Laboratories Enters Agreement For The Sale Of Its Entire Stake In Subsidiary, Svaas Wellness; No Financial Terms Disclosed

DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) Passes Key Peter Lynch Investment Screen

Asian Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading

Asian Equities Traded in the US as American Depositary Receipts Rise in Friday Trading

ESPR's Q4 Earnings Lag Estimates, Revenues Beat, Stock Down

Zacks Industry Outlook Highlights Teva Pharmaceuticals, Sandoz and Dr. Reddy's

Dr. Reddy's Said Company Has Received The Establishment Inspection Report On March 04, 2026. The FDA Has Classified The Inspection Outcome As Voluntary Action Indicated And Concluded That The Inspection Is Officially Closed Under 21 CFR 20.64(D)(3)

3 Generic Drug Stocks to Watch Despite Industry Headwinds